Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ulrich Trechsel"'
Autor:
Ian R. Reid, Jonathan R. Green, Kenneth W. Lyles, David M. Reid, Ulrich Trechsel, David J. Hosking, Dennis M. Black, Steven R. Cummings, R. Graham G. Russell, Erik F. Eriksen
Publikováno v:
Bone. 137
Zoledronate is the most potent and most long-acting bisphosphonate in clinical use, and is administered as an intravenous infusion. Its major uses are in osteoporosis, Paget's disease, and in myeloma and cancers to reduce adverse skeletal related eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c72625d6a3b0861e514fe5ed96054414
https://pubmed.ncbi.nlm.nih.gov/32353565
https://pubmed.ncbi.nlm.nih.gov/32353565
Autor:
Jean-Marc Kaufman, Jacques P. Brown, A Widmer, Philippe Jaeger, Zebulun D. Horowitz, Pierre J. Meunier, Jean-Pierre Devogelaer, Ulrich Trechsel, Jean-Jacques Body, Peter Burckhardt, Ian R. Reid, P J Richardson
Publikováno v:
Obstetrical & Gynecological Survey. 58:33-35
Although effective, oral bisphosphonate treatment for osteoporosis is limited by problems in compliance, gastrointestinal effects, and variable absorption. Intravenous bisphosphonates, given intermittently, might eliminate some problems of oral dosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ccbe8e30bdbbb69921e16ffe61256a
https://doi.org/10.1097/00006254-200301000-00020
https://doi.org/10.1097/00006254-200301000-00020
Autor:
Patrick Garnero, Jacques P. Brown, T. Fashola, Ulrich Trechsel, Stefan Goemaere, Dieter Felsenberg, Jean-Pierre Devogelaer, Peter Burckhardt, C. E. Ortmann, Jean-Jacques Body, Erik Fink Eriksen, Joel S. Krasnow, Kurt Lippuner, Liuska Sanna, Pierre J. Meunier, Göran Samsioe
Publikováno v:
Devogelaer, J P; Brown, J P; Burckhardt, P; Meunier, P J; Goemaere, S; Lippuner, K; Body, J J; Samsioe, G; Felsenberg, D; Fashola, T; Sanna, L; Ortmann, C E; Trechsel, U; Krasnow, J; Eriksen, E F; Garnero, P (2007). Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporosis international, 18(9), pp. 1211-8. London: Springer 10.1007/s00198-007-0367-3
In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, 3 or 5 years was well tolerated with no evidence of excessive bone turnover reduction or any safety signals. BMD increased significantly. Bone turnove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc05ca13091688b92c5345fe4dfeacc
https://pubmed.ncbi.nlm.nih.gov/17516022
https://pubmed.ncbi.nlm.nih.gov/17516022
Autor:
Michael J. Hooper, P J Richardson, Georg Leb, Göran Samsioe, Raffaele Di Micco, Philippe Jaeger, Pierre J. Meunier, Sergio Ortolani, A Widmer, Johann Broell, Jean-Jacques Body, Leon Verbruggen, Timothy M. Murray, Joachim Happ, Hans Mallmin, Jean-Marc Kaufman, Alessandro Rubinacci, Maria Sääf, Ian R. Reid, Jean-Pierre Devogelaer, Jacques P. Brown, Maria Luisa Brandi, Ulrich Trechsel, Peter Burckhardt, Zebulun D. Horowitz, Dieter Felsenberg, Andrea R. Genazzani, Jochen Ittner
Publikováno v:
The New England journal of medicine. 346(9)
Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aac10a8114593abf42dfb630f312e4f
https://pubmed.ncbi.nlm.nih.gov/12905962
https://pubmed.ncbi.nlm.nih.gov/12905962
Autor:
Helen Thurston, Hans Runge, Ulrich Trechsel, Roland Maeumbaed, Gerhard Krehan, T. Fashola, Peter Schlüter, Ralf H Wittenberg, Klaus J Burger, Ernest Schell
Publikováno v:
Arthritis Research & Therapy. 8:R35
Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige®) versus placebo and celecoxib in patients with knee oste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c67262ffceda76b8fd673322c9ae8c30
https://doi.org/10.1186/ar1854
https://doi.org/10.1186/ar1854